Rimegepant
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Rimegepant: From Migraine to Migraine with Brainstem Aura
One-Sentence Summary
Rimegepant is a CGRP receptor antagonist originally used to treat migraine, both acute treatment and prevention of episodic migraine. The TxGNN model predicts it may be effective for migraine with brainstem aura, a migraine subtype. There are no registered clinical trials for this subtype. 15 publications were compiled, but they address migraine in general and report no subtype-specific analysis, so the evidence is indirect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine disorder (the Singapore licence record contains no indication text) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, rimegepant is a CGRP (calcitonin gene-related peptide) receptor antagonist. Its efficacy in migraine with or without aura is established, and mechanistically it may be applicable to migraine with brainstem aura.
Migraine with brainstem aura is a migraine subtype that shares the CGRP-mediated trigeminovascular pathway with common migraine, so efficacy is biologically plausible. The phase 3 evidence in general migraine populations is indirect for this subtype, and none of the compiled literature reports a subtype-specific analysis.
One additional point of interest is that triptans and other vasoconstrictive agents have historically been cautioned in brainstem aura. A non-vasoconstrictive gepant could therefore be an attractive option. This has not been demonstrated. A 2026 imaging study of rimegepant's effect on cerebral and extracerebral arteries during migraine attacks addresses vascular effects in general, but not in this subtype.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 42143245 | 2026 | Systematic review and meta-analysis | J Headache Pain | Efficacy and tolerability of single-dose rimegepant 75 mg versus placebo for acute migraine in adults |
| 36739335 | 2023 | Review | CNS Drugs | Review of rimegepant for acute and preventive migraine treatment; more effective than placebo in pivotal phase III trials |
| 35790906 | 2022 | Network meta-analysis | J Headache Pain | Relative efficacy of lasmiditan versus rimegepant and ubrogepant for acute migraine |
| 41066271 | 2025 | Phase 3 open-label study | Cephalalgia | Long-term safety and effectiveness of rimegepant 75 mg ODT in Chinese adults with migraine |
| 41366286 | 2025 | Phase 4 open-label study | J Headache Pain | 24-week safety and tolerability of once-daily rimegepant 75 mg for episodic migraine prevention |
| 38307667 | 2024 | Review | Handb Clin Neurol | Overview of gepants; second-generation agents ubrogepant and rimegepant approved for acute migraine |
| 32270407 | 2020 | Review | Drugs | First approval of rimegepant ODT as an acute migraine treatment |
| 32993366 | 2021 | Review | Ann Pharmacother | Efficacy, safety and cost of ubrogepant, lasmiditan and rimegepant for acute migraine |
| 41574090 | 2026 | Prospective imaging study | Brain Commun | Rimegepant's effect on cerebral and extracerebral arteries during migraine attacks, examined as a non-vasoconstrictive option |
| 41652664 | 2026 | Retrospective analysis | Headache | Tolerability and effectiveness of off-label rimegepant for acute migraine in adolescents |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16702P | NURTEC ORALLY DISINTEGRATING TABLET 75MG | Tablet, orally disintegrating | Not stated in the licence record |
Safety Considerations
- Drug Interactions: 57 potential interactions were identified. The ones listed below are the first 20 returned, which include these Major-level interactions:
- Dexamethasone (Major)
- Lumacaftor (Major)
- Apalutamide (Major)
Moderate-level interactions in that set include aprepitant, clarithromycin, rolapitant, sulfasalazine, cobicistat, eltrombopag, ivacaftor, chloramphenicol, erythromycin, fluconazole, ketoconazole, tacrolimus, somatrem, somatotropin, abiraterone, afatinib and alpelisib. Many of these are CYP3A4 or transporter modulators.
- Cardiovascular signal: A 2026 pharmacovigilance analysis of FDA adverse event reports examined cardiac safety signals for CGRP antagonists. CGRP is a vasodilator, so its long-term blockade raises theoretical vascular concerns. This is relevant to any use in patients with vascular disease.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is biologically plausible, since this subtype shares the CGRP pathway with common migraine. However, no trials are registered, and no compiled literature analyses brainstem aura specifically. The evidence is indirect and extrapolated from general migraine populations.
To proceed, the following is needed:
- Subtype-specific data, such as a post hoc analysis of the pivotal trials in patients with brainstem aura, or a dedicated study
- Mechanism of action data (MOA) from DrugBank
- The HSA package insert, to confirm the approved indication, warnings and contraindications
- A vascular and cardiovascular safety assessment, given that brainstem aura patients are a population where vasoconstrictive agents have been cautioned
- A review of the clinically significant drug interactions, particularly the Major-level ones
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.